CLCNKB (Chloride channel protein ClC-Kb) variants and mutations
CLCNKB (also known as Chloride channel protein ClC-Kb) is a human protein-coding gene encoding a chloride channel protein ClC-Kb protein. It supports chloride reabsorption in the thick ascending limb and distal nephron, helping establish salt balance and the kidney's concentrating gradient. Biallelic loss-of-function variants cause Bartter syndrome type 3 and can sometimes mimic Gitelman syndrome. This analysis covers 1,096 CLCNKB variants and mutations. Of these, 78% have computational variant effect predictions. Disease context includes Bartter disease type 3, Bartter syndrome, and Gitelman syndrome. Example CLCNKB variants include E2D, E2K, and E2E.
Variant analysis overview
- Gene: CLCNKB
- Protein: Chloride channel protein ClC-Kb
- UniProt accession: P51801
- Organism: Homo sapiens
- Variants analyzed: 1096
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 913 unspecified-consequence records; 75 missense variants; 80 synonymous variants; 22 frameshift variants; 3 stop-gained variants; 1 in-frame deletions; 2 splice-region variants; 1 substitution
- Prediction scores: 860 variants have prediction scores (78% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Bartter disease type 3, Bartter syndrome, Gitelman syndrome, Bartter syndrome type 4, prostate carcinoma, epilepsy, familial focal, with variable foci 1, Proteinuria, Hematuria, autosomal dominant osteopetrosis 1, cardioverter defibrillator, hereditary disease, Sensorineural hearing impairment.
Protein structure and variant hotspots
- Protein features: 10 transmembrane segments; 2 domains; 6 binding sites; 1 post-translational modification sites.
- Structural context: 512 variants have structural context.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CLCNKB variants
Examples include E2D, E2K, E2E, E3D, E3K, E3Q, F4L, F4S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- E2D (p.Glu2Asp), 1000Genomes rs536104811, gnomAD rs536104811, REVEL 0.39, CADD 22.00
- E2K (p.Glu2Lys), gnomAD 1-16044496-G-A, REVEL 0.56, CADD 25.20
- E2E (p.Glu2Glu), gnomAD 1-16044498-G-A, CADD 3.58
- E3D (p.Glu3Asp), rs768510442, ClinGen CA623135, ClinVar RCV002904949, ClinVar RCV003170574, REVEL 0.15, CADD 15.20, Conflicting interpretations, not provided; Inborn genetic diseases
- E3K (p.Glu3Lys), gnomAD rs1444724783, REVEL 0.57, CADD 25.20
- E3Q (p.Glu3Gln), NCI-TCGA Cosmic COSV6515, cosmic curated COSV65159, Variant assessed as somatic; moderate impact.
- F4L (p.Phe4Leu), rs34851419, ClinGen CA623136, ClinVar RCV000968510, ClinVar RCV001289387, REVEL 0.23, CADD 14.60, Benign, not provided; not specified
- F4S (p.Phe4Ser), TOPMed rs1208815673, gnomAD rs1208815673, REVEL 0.18, CADD 23.50
- F4F (p.Phe4Phe), rs34851419, gnomAD 1-16044504-T-C, CADD 8.17
- V5G (p.Val5Gly), gnomAD 1-16044505-GT-G, CADD 24.30
- V5L (p.Val5Leu), gnomAD 1-16044505-G-T, REVEL 0.38, CADD 23.80
- V5A (p.Val5Ala), gnomAD 1-16044506-T-C, REVEL 0.40, CADD 20.60
- V5V (p.Val5Val), gnomAD 1-16044507-G-A, CADD 2.78
- G6E (p.Gly6Glu), ExAC rs747945822, gnomAD rs747945822, REVEL 0.51, CADD 24.50
- G6R (p.Gly6Arg), gnomAD rs1295011210, REVEL 0.50, CADD 23.40
- G6W (p.Gly6Trp), gnomAD 1-16044508-G-T, REVEL 0.61, CADD 25.30
- G6G (p.Gly6Gly), gnomAD 1-16044510-G-A, CADD 5.97
- L7A (p.Leu7Ala), rs953686324, gnomAD 1-16044506-T-TG, CADD 25.00
- L7L (p.Leu7Leu), rs1213749912, gnomAD 1-16044511-C-T, CADD 8.40
- L7P (p.Leu7Pro), gnomAD 1-16044512-T-C, REVEL 0.72, CADD 24.90
- R8C (p.Arg8Cys), rs985164800, TOPMed rs985164800, gnomAD rs985164800, REVEL 0.60, CADD 24.90, Variant assessed as somatic; moderate impact.
- R8H (p.Arg8His), rs387907411, ClinGen CA216012, ClinVar RCV000054567, ClinVar RCV002483072, REVEL 0.30, CADD 16.00, Uncertain significance, Bartter disease type 4B; Bartter disease type 3
- R8S (p.Arg8Ser), gnomAD 1-16044514-C-A, REVEL 0.48, CADD 22.50
- R8R (p.Arg8Arg), rs1204707218, gnomAD 1-16044516-T-C, CADD 0.67
- E9K (p.Glu9Lys), gnomAD 1-16044517-G-A, REVEL 0.60, CADD 23.80
- E9E (p.Glu9Glu), rs772984104, gnomAD 1-16044519-A-G, CADD 3.81
- E9D (p.Glu9Asp), gnomAD 1-16044519-A-T, REVEL 0.32, CADD 10.70
- G10A (p.Gly10Ala), TOPMed rs1022537062, gnomAD rs1022537062, REVEL 0.57, CADD 23.30, Uncertain significance
- G10V (p.Gly10Val), TOPMed rs1022537062, gnomAD rs1022537062, REVEL 0.76, CADD 23.80, Uncertain significance, Bartter disease type 3; Bartter disease type 4B
- G10C (p.Gly10Cys), gnomAD 1-16044520-G-T, REVEL 0.72, CADD 24.10
- G10G (p.Gly10Gly), gnomAD 1-16044522-C-T, CADD 6.37
- S11F (p.Ser11Phe), ExAC rs760357463, gnomAD rs760357463, REVEL 0.34, CADD 21.30, Uncertain significance, Bartter disease type 3; Bartter disease type 4B
- S11P (p.Ser11Pro), gnomAD 1-16044521-GC-G, CADD 22.30
- S11S (p.Ser11Ser), rs766031319, gnomAD 1-16044525-C-A, CADD 4.93
- S12L (p.Ser12Leu), Ensembl rs2023036588, REVEL 0.41, CADD 22.40
- S12P (p.Ser12Pro), NCI-TCGA TCGA novel, REVEL 0.21, CADD 14.20, Variant assessed as somatic; moderate impact.
- S12* (p.Ser12Ter), gnomAD 1-16044527-C-A, CADD 37.00
- S12S (p.Ser12Ser), rs775410059, gnomAD 1-16044528-A-G, CADD 0.39
- G13E (p.Gly13Glu), gnomAD 1-16044528-AGG-A, CADD 24.40
- G13G (p.Gly13Gly), gnomAD 1-16044531-G-T, CADD 9.90
- N14D (p.Asn14Asp), gnomAD rs1167698353, REVEL 0.17, CADD 5.53, Likely benign, Inborn genetic diseases
- N14K (p.Asn14Lys), gnomAD rs1417735592, REVEL 0.15, CADD 2.19
- N14T (p.Asn14Thr), rs1260198649, gnomAD 1-16044527-CA-C, CADD 0.12
- N14H (p.Asn14His), gnomAD 1-16044532-A-C, REVEL 0.24, CADD 8.16
- N14S (p.Asn14Ser), gnomAD 1-16044532-AACCCT, CADD 23.60
- N14Y (p.Asn14Tyr), gnomAD 1-16044532-A-T, REVEL 0.33, CADD 15.30
- P15R (p.Pro15Arg), TOPMed rs1412014358, gnomAD rs1412014358, REVEL 0.65, CADD 23.50, Uncertain significance, Inborn genetic diseases
- P15S (p.Pro15Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P15H (p.Pro15His), gnomAD 1-16044536-C-A, REVEL 0.53, CADD 23.60
- P15L (p.Pro15Leu), gnomAD 1-16044536-C-T, REVEL 0.61, CADD 19.10
- P15P (p.Pro15Pro), gnomAD 1-16044537-T-A, CADD 0.45
- V16E (p.Val16Glu), gnomAD 1-16044539-T-A, REVEL 0.63, CADD 24.80
- V16G (p.Val16Gly), gnomAD 1-16044539-T-G, REVEL 0.70, CADD 24.80
- V16V (p.Val16Val), gnomAD 1-16044540-G-T, CADD 6.15
- T17N (p.Thr17Asn), gnomAD rs866959922, REVEL 0.12, CADD 11.30
- T17I (p.Thr17Ile), gnomAD 1-16044542-C-T, REVEL 0.15, CADD 16.40
- T17T (p.Thr17Thr), gnomAD 1-16044543-T-G, CADD 1.39
- L18V (p.Leu18Val), gnomAD 1-16044544-C-G, REVEL 0.40, CADD 21.90
- L18L (p.Leu18Leu), rs759045664, gnomAD 1-16044544-C-T, CADD 7.88
- L18M (p.Leu18Met), gnomAD 1-16044544-C-A, REVEL 0.36, CADD 23.40
- L18P (p.Leu18Pro), gnomAD 1-16044545-T-C, REVEL 0.68, CADD 23.20
- Q19* (p.Gln19Ter), TOPMed rs1355997573, gnomAD rs1355997573, CADD 36.00
- Q19K (p.Gln19Lys), TOPMed rs1355997573, gnomAD rs1355997573, REVEL 0.23, CADD 7.74
- p.Gln19 Leu21del, gnomAD 1-16044542-CTCTGC, CADD 16.30
- Q19P (p.Gln19Pro), gnomAD 1-16044548-A-C, REVEL 0.26, CADD 0.60
- E20* (p.Glu20Ter), Ensembl rs2124081139
- E20K (p.Glu20Lys), gnomAD 1-16044550-G-A, REVEL 0.55, CADD 22.00
- E20G (p.Glu20Gly), gnomAD 1-16044551-A-G, REVEL 0.67, CADD 26.40
- E20E (p.Glu20Glu), rs764512896, gnomAD 1-16044552-G-A, CADD 7.31
- E20D (p.Glu20Asp), gnomAD 1-16044552-G-T, REVEL 0.55, CADD 22.00
- L21P (p.Leu21Pro), TOPMed rs1363752566, gnomAD rs1363752566, REVEL 0.59, CADD 24.40
- L21R (p.Leu21Arg), TOPMed rs1363752566, gnomAD rs1363752566
- L21M (p.Leu21Met), gnomAD 1-16044553-C-A, REVEL 0.47, CADD 22.20
- L21L (p.Leu21Leu), rs1214974456, gnomAD 1-16044555-G-A, CADD 0.17
- W22* (p.Trp22Ter), gnomAD rs1279122450, CADD 38.00
- W22G (p.Trp22Gly), Ensembl rs1570326573
- W22L (p.Trp22Leu), gnomAD rs1279122450, REVEL 0.72, CADD 24.50
- G23D (p.Gly23Asp), TOPMed rs2023038098
- G23S (p.Gly23Ser), Ensembl rs2023038048, REVEL 0.29, CADD 18.50
- G23A (p.Gly23Ala), gnomAD 1-16044556-TG-T, CADD 23.90
- G23V (p.Gly23Val), gnomAD 1-16044560-G-T, REVEL 0.46, CADD 16.50
- G23G (p.Gly23Gly), rs1345354024, gnomAD 1-16044561-C-A, CADD 4.20
- P24H (p.Pro24His), ExAC rs387907412, TOPMed rs387907412, REVEL 0.63, CADD 22.50, Uncertain significance
- P24L (p.Pro24Leu), rs387907412, ClinGen CA216014, ClinVar RCV000054568, ExAC rs387907412, REVEL 0.63, CADD 22.60, Uncertain significance, not provided
- P24S (p.Pro24Ser), TOPMed rs2023038229
- P24P (p.Pro24Pro), rs757836001, gnomAD 1-16044564-C-T, CADD 0.22
- C25S (p.Cys25Ser), TOPMed rs1336065376, gnomAD rs1336065376, REVEL 0.74, CADD 23.60
- C25Y (p.Cys25Tyr), gnomAD rs1212383858, REVEL 0.78, CADD 23.40
- C25V (p.Cys25Val), gnomAD 1-16044560-GC-G, CADD 16.40
- C25R (p.Cys25Arg), gnomAD 1-16044565-T-C, REVEL 0.75, CADD 23.20
- P26A (p.Pro26Ala), TOPMed rs1280512118, gnomAD rs1280512118
- P26L (p.Pro26Leu), rs1445924613, NCI-TCGA Cosmic COSV1009, cosmic curated COSV10099, NCI-TCGA Cosmic COSV6516, REVEL 0.70, CADD 23.70, Uncertain significance, Inborn genetic diseases
- P26S (p.Pro26Ser), TOPMed rs1280512118, gnomAD rs1280512118, REVEL 0.61, CADD 23.60
- P26T (p.Pro26Thr), TOPMed rs1280512118, gnomAD rs1280512118, REVEL 0.69, CADD 23.50
- P26P (p.Pro26Pro), rs376899737, gnomAD 1-16044570-C-A, CADD 6.72
- R27C (p.Arg27Cys), cosmic curated COSV65160, ESP rs370236747, ExAC rs370236747, TOPMed rs370236747, REVEL 0.53, CADD 22.80, Uncertain significance, Inborn genetic diseases; Bartter disease type 3; Bartter disease type 4B
- R27G (p.Arg27Gly), rs370236747, ClinGen CA338629954, ClinVar RCV004444290, ESP rs370236747, REVEL 0.37, CADD 17.60, Uncertain significance, Inborn genetic diseases
- R27H (p.Arg27His), 1000Genomes rs2015352, ESP rs2015352, ExAC rs2015352, TOPMed rs2015352, REVEL 0.24, CADD 15.10, Benign
- R27L (p.Arg27Leu), rs2015352, ClinGen CA623148, cosmic curated COSV65159, ClinVar RCV000516547, REVEL 0.29, CADD 18.60, Benign, not specified; not provided; Bartter disease type 3
- R27P (p.Arg27Pro), 1000Genomes rs2015352, ESP rs2015352, ExAC rs2015352, TOPMed rs2015352, REVEL 0.57, CADD 16.70, Benign
- R27A (p.Arg27Ala), gnomAD 1-16044567-TC-T, CADD 23.60
- R27S (p.Arg27Ser), gnomAD 1-16044571-C-A, REVEL 0.22, CADD 13.30
- R27R (p.Arg27Arg), gnomAD 1-16044573-C-A, CADD 6.93
- I28L (p.Ile28Leu), Ensembl rs924135805
- I28V (p.Ile28Val), gnomAD 1-16044574-A-G, REVEL 0.14, CADD 0.86
- I28I (p.Ile28Ile), rs1394681594, gnomAD 1-16044576-C-A, CADD 5.98
- R29C (p.Arg29Cys), rs140923370, cosmic curated COSV65160, ESP rs140923370, ExAC rs140923370, REVEL 0.61, CADD 23.20, Uncertain significance, Inborn genetic diseases
- R29H (p.Arg29His), rs544582273, ClinGen CA623152, cosmic curated COSV10099, ClinVar RCV002937286, REVEL 0.47, CADD 22.80, Uncertain significance, not provided; Bartter disease type 3; Bartter disease type 4B
- R29L (p.Arg29Leu), 1000Genomes rs544582273, ExAC rs544582273, TOPMed rs544582273, gnomAD rs544582273, REVEL 0.40, CADD 22.60, Uncertain significance, Bartter disease type 3; Bartter disease type 4B
- R29S (p.Arg29Ser), gnomAD 1-16044577-C-A, REVEL 0.44, CADD 18.50
- R29R (p.Arg29Arg), gnomAD 1-16044579-C-G, CADD 6.91
- R30* (p.Arg30Ter), 1000Genomes rs200835418, ExAC rs200835418, TOPMed rs200835418, gnomAD rs200835418, CADD 35.00
- R30Q (p.Arg30Gln), TOPMed rs1400214347, gnomAD rs1400214347, REVEL 0.50, CADD 21.70, Uncertain significance, not provided; Bartter disease type 3; Bartter disease type 4B
- R30R (p.Arg30Arg), gnomAD 1-16044580-C-A, CADD 5.23
- R30L (p.Arg30Leu), gnomAD 1-16044581-G-T, REVEL 0.54, CADD 22.30
- R30P (p.Arg30Pro), gnomAD 1-16044581-G-C, REVEL 0.59, CADD 22.30
- G31A (p.Gly31Ala), ExAC rs771963940, TOPMed rs771963940, gnomAD rs771963940, REVEL 0.19, CADD 11.00
- G31S (p.Gly31Ser), gnomAD rs1316084166, REVEL 0.07, CADD 11.70
- G31V (p.Gly31Val), gnomAD 1-16044584-G-T, REVEL 0.15, CADD 14.90
- G31D (p.Gly31Asp), gnomAD 1-16044584-G-A, REVEL 0.22, CADD 13.90
- G31G (p.Gly31Gly), gnomAD 1-16044585-C-A, CADD 7.84
- I32M (p.Ile32Met), gnomAD rs1302477743
- I32T (p.Ile32Thr), rs1431164824, gnomAD rs1431164824, REVEL 0.24, CADD 19.40, Variant assessed as somatic; moderate impact.
- I32V (p.Ile32Val), gnomAD 1-16044586-A-G, REVEL 0.16, CADD 1.74
- I32I (p.Ile32Ile), gnomAD 1-16044588-C-A, CADD 8.29
- R33* (p.Arg33Ter), ESP rs374439723, ExAC rs374439723, gnomAD rs374439723, CADD 36.00
- R33Q (p.Arg33Gln), rs746767761, ClinGen CA623156, NCI-TCGA Cosmic COSV6516, cosmic curated COSV65161, REVEL 0.16, CADD 16.40, Uncertain significance, Bartter disease type 3; Bartter disease type 4B; Inborn genetic diseases
- R33R (p.Arg33Arg), gnomAD 1-16044589-C-A, CADD 7.03
- G34C (p.Gly34Cys), Ensembl rs2124081334, REVEL 0.50, CADD 33.00
- G34D (p.Gly34Asp), rs762515275, ClinGen CA623180, ClinVar RCV001935343, ExAC rs762515275, REVEL 0.14, CADD 18.00, Uncertain significance, not provided
- G34V (p.Gly34Val), ExAC rs762515275, TOPMed rs762515275, gnomAD rs762515275, REVEL 0.17, CADD 22.60, Uncertain significance
- G34S (p.Gly34Ser), gnomAD 1-16044592-G-A, REVEL 0.31, CADD 32.00
- G35C (p.Gly35Cys), TOPMed rs1392045264, gnomAD rs1392045264, REVEL 0.16, CADD 19.30
- G35D (p.Gly35Asp), TOPMed rs1403773053
- G35G (p.Gly35Gly), rs138768237, gnomAD 1-16045562-C-A, CADD 8.89
- L36W (p.Leu36Trp), gnomAD 1-16045561-GC-G, CADD 24.20
- L36P (p.Leu36Pro), gnomAD 1-16045564-T-C, REVEL 0.69, CADD 25.90
- E37Q (p.Glu37Gln), gnomAD rs1252959928, REVEL 0.18, CADD 19.60
- E37K (p.Glu37Lys), gnomAD 1-16045566-G-A, REVEL 0.34, CADD 20.40
- E37E (p.Glu37Glu), rs147391626, gnomAD 1-16045568-G-A, CADD 7.76
- W38R (p.Trp38Arg), rs375301415, ClinGen CA623184, cosmic curated COSV65162, ClinVar RCV002135342, REVEL 0.37, CADD 22.90, Conflicting interpretations, not provided; not specified
- W38L (p.Trp38Leu), gnomAD 1-16045570-G-T, REVEL 0.57, CADD 23.90
- W38C (p.Trp38Cys), gnomAD 1-16045571-G-T, REVEL 0.53, CADD 22.90
- L39P (p.Leu39Pro), Ensembl rs2124083798
- L39L (p.Leu39Leu), rs143673726, gnomAD 1-16045574-G-A, CADD 8.83
- K40E (p.Lys40Glu), gnomAD rs1476180677
- K40M (p.Lys40Met), gnomAD 1-16045576-A-T, REVEL 0.67, CADD 24.50
- K40K (p.Lys40Lys), rs1187994731, gnomAD 1-16045577-G-A, CADD 8.83
- Q41R (p.Gln41Arg), ExAC rs759799517, gnomAD rs759799517, REVEL 0.23, CADD 15.90
- K42R (p.Lys42Arg), gnomAD 1-16045582-A-G, REVEL 0.20, CADD 15.00
- K42K (p.Lys42Lys), rs765392974, gnomAD 1-16045583-G-A, CADD 6.77
- L43I (p.Leu43Ile), ESP rs148698605, ExAC rs148698605, TOPMed rs148698605, gnomAD rs148698605, REVEL 0.47, CADD 12.60, Uncertain significance
- L43V (p.Leu43Val), ESP rs148698605, ExAC rs148698605, TOPMed rs148698605, gnomAD rs148698605, REVEL 0.41, CADD 12.70, Uncertain significance, not provided; Bartter disease type 3; Bartter disease type 4B
- L43P (p.Leu43Pro), gnomAD 1-16045584-CT-C, CADD 23.60
- L43L (p.Leu43Leu), gnomAD 1-16045586-C-G, CADD 2.75
- F44I (p.Phe44Ile), NCI-TCGA Cosmic COSV6516, cosmic curated COSV65160, Variant assessed as somatic; moderate impact.
- F44Y (p.Phe44Tyr), ExAC rs777700978, TOPMed rs777700978, gnomAD rs777700978, REVEL 0.63, CADD 23.70, Uncertain significance, Inborn genetic diseases; Bartter disease type 3; Bartter disease type 4B
- F44L (p.Phe44Leu), gnomAD 1-16045587-T-C, REVEL 0.62, CADD 22.90
- F44V (p.Phe44Val), gnomAD 1-16045587-T-G, REVEL 0.61, CADD 20.10
- R45C (p.Arg45Cys), rs367552783, ClinGen CA623191, ClinVar RCV003088295, ClinVar RCV005050726, REVEL 0.30, CADD 19.40, Uncertain significance, Bartter disease type 3; Bartter disease type 4B; not provided
- R45G (p.Arg45Gly), ESP rs367552783, ExAC rs367552783, TOPMed rs367552783, gnomAD rs367552783, REVEL 0.61, CADD 22.20, Uncertain significance
- R45H (p.Arg45His), rs551946850, ClinGen CA623192, ClinVar RCV002606063, 1000Genomes rs551946850, REVEL 0.33, CADD 18.00, Uncertain significance, not provided
- R45L (p.Arg45Leu), gnomAD 1-16045591-G-T, REVEL 0.62, CADD 22.30
- R45P (p.Arg45Pro), gnomAD 1-16045591-G-C, REVEL 0.74, CADD 23.00
- L46P (p.Leu46Pro), gnomAD rs1354106899, REVEL 0.46, CADD 19.10
- G47D (p.Gly47Asp), ExAC rs781091568, TOPMed rs781091568, gnomAD rs781091568, REVEL 0.78, CADD 25.30
- G47V (p.Gly47Val), ExAC rs781091568, TOPMed rs781091568, gnomAD rs781091568, REVEL 0.74, CADD 25.20
- G47G (p.Gly47Gly), gnomAD 1-16045598-C-A, CADD 0.57
- E48* (p.Glu48Ter), NCI-TCGA Cosmic COSV1009, cosmic curated COSV10099, CADD 43.00, Variant assessed as somatic; high impact.
- E48G (p.Glu48Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E48K (p.Glu48Lys), ExAC rs769604665, TOPMed rs769604665, gnomAD rs769604665, REVEL 0.82, CADD 26.60, Uncertain significance, Inborn genetic diseases
- E48E (p.Glu48Glu), rs2023076642, gnomAD 1-16045601-G-A, CADD 8.80
- D49E (p.Asp49Glu), NCI-TCGA Cosmic COSV6516, cosmic curated COSV65161, Variant assessed as somatic; moderate impact.
- D49L (p.Asp49Leu), gnomAD 1-16045601-GGA-G, CADD 31.00
- D49N (p.Asp49Asn), gnomAD 1-16045602-G-A, REVEL 0.81, CADD 28.80
- D49D (p.Asp49Asp), rs1225742667, gnomAD 1-16045604-C-T, CADD 10.40
- W50* (p.Trp50Ter), gnomAD rs1253263367, CADD 43.00
- W50L (p.Trp50Leu), rs2023076796, gnomAD 1-16045604-C-CT, CADD 28.90
- Y51* (p.Tyr51Ter), TOPMed rs1324713934, gnomAD rs1324713934
- Y51H (p.Tyr51His), TOPMed rs1336262921, gnomAD rs1336262921
Public CLCNKB analysis runs
- CLCNKB analysis run — CLCNKB (1,096 variants) — completed 2026-08-22